Results 51 to 60 of about 3,776 (143)

Therapeutic potential of natural products in cancer immunotherapy: Advances and challenges

British Journal of Pharmacology, EarlyView.
This review systematically outlines the mechanisms underlying tumour immunotherapy resistance and elucidates the role of natural products in enhancing therapeutic efficacy as immunomodulatory adjuvants. Abstract Immunotherapy has emerged as a clinically pivotal approach in cancer treatment, but its application remains limited to a small subset of ...
Rao Hu, Kaibin Dai, Zhensheng Lin, Mingfang Ye, Minfeng Chen, Xiaobo Li, Dongmei Zhang   +6 more
wiley   +1 more source

Treatment strategies for interstitial granulomatous dermatitis: Systematic review and expert opinion

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Systematic review of 108 studies with a total of 182 patients with interstitial granulomatous dermatitis (IGD). IGD was frequently associated with systemic conditions or drug exposure. Management includes careful medication review and prompt withdrawal of potential triggers. Corticosteroids (systemic and topical) were commonly effective, while biologic
Francesco Bellinato, Sara Salvagno, Chiara Colato, Paolo Gisondi, Giampiero Girolomoni   +4 more
wiley   +1 more source

Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial

BMC Cancer, 2022
Background Trials investigating neoadjuvant treatment with immune checkpoint inhibitors (ICI) in patients with melanoma have shown high clinical and pathologic response rates.
Maartje W. Rohaan, Emma H. A. Stahlie, Viola Franke, Lisanne P. Zijlker, Sofie Wilgenhof, Vincent van der Noort, Alexander C. J. van Akkooi, John B. A. G. Haanen   +7 more
doaj   +1 more source

Mesothelin as Biomarker and Therapeutic Target for Immunotherapy in Cancer

MedComm, Volume 7, Issue 10, October 2026.
Mesothelin overexpression activate important pathways like nuclear factor k‐light‐chain‐enhancer of activated B cells (NF‐κB) and interleukin‐6 (IL‐6). This in turn causes numerous cancers, such as pancreatic and ovarian cancers. MSLN‐targeting immunotherapies, like monoclonal antibodies, have shown efficacy.
Manoj Kumar Gupta, Ramakrishna Vadde, Ganji Purnachandra Nagaraju   +2 more
wiley   +1 more source

A phase II study of talimogene laherparepvec followed by talimogene laherparepvec + nivolumab in refractory T cell and NK cell lymphomas, cutaneous squamous cell carcinoma, Merkel cell carcinoma, and other rare skin tumors (NCI #10057).

, 2018
TPS219 Background: Talimogene laherparepvec, a modified herpes virus agent, induces a response in 65% of injected melanoma tumors. The combination of talimogene laherparepvec with ipilimumab or pembrolizumab appears promising in clinical trials of ...
Guilherme Rabinowits, Sumana Devata, Nicole R. LeBoeuf, Janice M. Mehnert, James Steven Goydos, Melissa Amber Burgess, Andrew Zloza, Helen X. Chen, Ann W. Silk, Igor Puzanov, Howard Kaufman, Dirk Moore   +11 more
core   +1 more source

Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma [PDF]

, 2018
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study.
Theodore F. Logan, Jennifer Gansert, Lisa Chen, John Glaspy, Jason Chesney, Axel Hauschild, Puzanov, Igor, Kaufman, Howard L, Kim, Jenny J, Mohammed M. Milhem, Jenny J. Kim, Chen, Lisa, Hamid, Omid, Parminder Singh, Frances Collichio, Philip Friedlander, Logan, Theodore F, Andtbacka, Robert HI, Hauschild, Axel, Omid Hamid, Merrick Ross, Gansert, Jennifer, Howard L. Kaufman, Robert H.I. Andtbacka, Igor Puzanov, Collichio, Frances, Lebbé, Celeste, Celeste Lebbé, Friedlander, Philip, Milhem, Mohammed M, Chesney, Jason, Glaspy, John, Claus Garbe, Garbe, Claus, Ross, Merrick, Singh, Parminder   +35 more
core   +1 more source

Biodistribution, shedding, and transmissibility of the oncolytic virus talimogene laherparepvec in patients with melanomaResearch in context

EBioMedicine, 2019
Background: Talimogene laherparepvec (T-VEC) is an intralesionally delivered, modified herpes simplex virus type-1 oncolytic immunotherapy. The biodistribution, shedding, and potential transmission of T-VEC was systematically evaluated during and after ...
Robert H.I. Andtbacka, Thomas Amatruda, John Nemunaitis, Jonathan S. Zager, John Walker, Jason A. Chesney, Kate Liu, Cheng-Pang Hsu, Cheryl A. Pickett, Janice M. Mehnert   +9 more
doaj   +1 more source

Radiotherapy Enhances the Oncolytic Efficacy of the Novel Oncolytic Herpesvirus VG161 and Amplifies Its Antitumor Immunity in Breast Cancer

Advanced Science, Volume 13, Issue 52, 18 September 2026.
RT promotes VG161 replication in BC and its immunostimulatory transgenes expression, which is mediated by the upregulation of GADD34 and HVEM caused by RT. The combination therapy with VG161 and RT increases the abundances of tumor‐infiltrating lymphocytes and elicits potent systemic antitumor immunity, thereby effectively inhibiting local tumors and ...
Lijuan Lyu, Ming Yi, Ji Chen, Zeda Zhao, Ruocen Liao, Yingnan Wang, Shengtao Hu, Jun Ding, Ronghua Zhao, William Jia, Yinan Shen, Yongchang Wei, Kongming Wu, Zhijun Dai   +13 more
wiley   +1 more source

Microbial Signals in Cancer: Dissecting Host–Microbiota–Tumor Interactions and Potential Therapeutic Strategy

MedComm, Volume 7, Issue 9, September 2026.
Microbial signals from gut and tumor‐resident bacteria, fungi, viruses, and bacteriophages reshape immune and metabolic networks within the tumor microenvironment, thereby influencing cancer progression, treatment response. Therapeutic modulations, including dietary interventions, probiotics, antibiotics, fecal microbiota transplantation, engineered ...
Juan Lu, Mengjuan Xuan, Liang Yu, Zhongyang Xie, Qingfei Chu, Shihui Wei, Tuokai Wang, Chen Xue, Lanjuan Li   +8 more
wiley   +1 more source

Complete response with talimogene laherparepvec in recurrent melanoma of the ear: A case report.

, 2020
The current standard of care for cutaneous melanoma of the ear is surgical excision. This approach may result in unfavorable functional and cosmetic outcomes.
Eisenberg, Burton L, Hsu, Ashley C, Kokot, Niels C, Thomas, Jacob S   +3 more
core   +1 more source